Mantle Cell Lymphoma Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight's "Mantle Cell Lymphoma Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Mantle Cell Lymphoma pipeline landscape. It covers the Mantle Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mantle Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Mantle Cell Lymphoma Pipeline? @ https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Mantle Cell Lymphoma Pipeline Report

* On May 22, 2026- BeOne Medicines announced a phase 3 study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
* On May 18, 2026- Acerta Pharma BV conducted a clinical trial is a Phase 2, multicenter, (approximately 70 global centers), open-label study in subjects with histologically documented MCL, who have relapsed after, or were refractory to, greater than or equal to 1 (but not > 5) prior treatment regimens. Subjects will be enrolled and will take 100 mg of acalabrutinib twice per day (BID) in repeated 28-day cycles.
* On May 18, 2026- BeOne Medicines announced a phase 3 study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
* On May 15, 2026- Loxo Oncology Inc . initiated a phase 3 study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.
* On May 14, 2026- Canadian Cancer Trials Group conducted a phase II study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
* DelveInsight's Mantle Cell Lymphoma Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Mantle Cell Lymphoma treatment.
* The leading Mantle Cell Lymphoma Companies such as Roche, Merck Sharp & Dohme LLC, OncoNano Medicine, Inc., March Biosciences, Wellington Zhaotai Therapies Limited, Regeneron Pharmaceuticals, Nurix Therapeutics, Inc., Cellectar Biosciences, Inc., Adicet Therapeutics, Oncternal Therapeutics, Inc., AstraZeneca, Atara Biotherapeutics, Accutar Biotechnology Inc., AbbVie, Galapagos NV and others.
* Promising Mantle Cell Lymphoma Therapies such as Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Ibrutinib, Pirtobrutinib, Acalabrutinib , and others.

Want to know which companies are leading innovation in Mantle Cell Lymphoma? @ Mantle Cell Lymphoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Mantle Cell Lymphoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Mantle Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to the Mantle Cell Lymphoma.

Mantle Cell Lymphoma Overview

Mantle cell lymphoma (MCL) is a rare and aggressive form of B-cell non-Hodgkin lymphoma, primarily distinguished by the characteristic t (11; 14) chromosomal translocation, leading to the overexpression of cyclin D1. This genetic alteration drives the uncontrolled proliferation of B-cells. MCL presents with a range of morphological variants, which can complicate its diagnosis, although some cases remain straightforward. Clinically, MCL tends to follow an aggressive course, but a less common, indolent leukemia variant has also been observed. Despite its rarity, understanding MCL's distinct genetic and clinical features is crucial for accurate diagnosis and treatment. The aggressive form of MCL often involves rapid progression, leading to widespread lymphadenopathy, extranodal involvement, and poor prognosis without timely intervention. In contrast, the indolent variant of MCL may present with a more chronic course, sometimes resembling chronic lymphocytic leukemia, and often has a better response to treatment.

Mantle Cell Lymphoma Emerging Drugs Profile

* Glofitamab: Roche

Glofitamab (Columvi) is a CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi is designed with a novel 2:1 structural format. This T-cell-engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is being investigated as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Glofitamab has also been granted Orphan Drug Designation by the US FDA for the treatment of Mantle Cell Lymphoma. Currently, the drug is in Phase III stage of its development for the treatment of Mantle Cell Lymphoma.

* Zilovertamab vedotin: Merck Sharp & Dohme LLC

Zilovertamab vedotin is an Antibody-Drug Conjugate (ADC) composed of a monoclonal antibody against the Tumor-Associated Antigen (TAA) Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the ROR1-expressing cancer cells, through an as of yet unknown mechanism of action. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival. Currently, the drug is in Phase II stage of its development for the treatment of Mantle Cell Lymphoma.

* ONM-501: OncoNano Medicine, Inc.

ONM-501 is a dual-activating STING (STimulator of INterferon Genes) agonist delivered to the tumor microenvironment to produce dendritic cell maturation, prime cytotoxic T cells, and induce a strong adaptive immune response. Preclinical data has shown evidence that ONM-501 prolongs STING activation with a low potential for systemic side effects, including cytokine storms. In murine models, ONM-501 has demonstrated antitumor efficacy, and when combined with checkpoint inhibition, produces a synergistic tumor cell death. Currently, the drug is in Phase I stage of its development for the treatment of Mantle Cell Lymphoma.

* MB 105: March Biosciences

MB-105, selectively targets CD5, a widely expressed antigen both in normal and malignant T-cells. CD5 is a cell surface marker that is commonly expressed in normal T-cells, thymocytes, and a small subset of B-cells. It is widely expressed in T-cell malignancies. It is further highly expressed in T-cell acute lymphoblastic leukemia and certain B-cell malignancies such as Mantle Cell Lymphoma (MCL) and Chronic Leukocytic Leukemia (CLL). The specific engineering of MB-105 CAR enables preservation of normal T-cells, while maintaining cytotoxicity against CD5+ tumor cells, avoiding risk of severe immunodeficiency. CAR T-cell expansion promotes early terminal T-cell differentiation, resulting in potent but short-lived effector cells incapable of driving patient responses. . Currently, the drug is in Preclinical stage of its development for the treatment of Mantle Cell Lymphoma.

If you're tracking ongoing Mantle Cell Lymphoma Clinical trials @ Mantle Cell Lymphoma Treatment Drugs [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Mantle Cell Lymphoma Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Mantle Cell Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mantle Cell Lymphoma Treatment.
* Mantle Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Mantle Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mantle Cell Lymphoma market.

Mantle Cell Lymphoma Companies

Roche, Merck Sharp & Dohme LLC, OncoNano Medicine, Inc., March Biosciences, Wellington Zhaotai Therapies Limited, Regeneron Pharmaceuticals, Nurix Therapeutics, Inc., Cellectar Biosciences, Inc., Adicet Therapeutics, Oncternal Therapeutics, Inc., AstraZeneca, Atara Biotherapeutics, Accutar Biotechnology Inc., AbbVie, Galapagos NV and others.

Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Mantle Cell Lymphoma Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Mantle Cell Lymphoma Pipeline Report @ Mantle Cell Lymphoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Mantle Cell Lymphoma Pipeline Report

* Coverage- Global
* Mantle Cell Lymphoma Companies- Roche, Merck Sharp & Dohme LLC, OncoNano Medicine, Inc., March Biosciences, Wellington Zhaotai Therapies Limited, Regeneron Pharmaceuticals, Nurix Therapeutics, Inc., Cellectar Biosciences, Inc., Adicet Therapeutics, Oncternal Therapeutics, Inc., AstraZeneca, Atara Biotherapeutics, Accutar Biotechnology Inc., AbbVie, Galapagos NV and others.
* Mantle Cell Lymphoma Therapies- Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Ibrutinib, Pirtobrutinib, Acalabrutinib , and others.
* Mantle Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Mantle Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Mantle Cell Lymphoma treatment landscape in this detailed analysis @ Mantle Cell Lymphoma Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Mantle Cell Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Mantle Cell Lymphoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Venetoclax: AbbVie
* Mid Stage Products (Phase II)
* Ixazomib: Takeda
* Early Stage Products (Phase I)
* PEP07: PharmaEngine
* Preclinical and Discovery Stage Products
* Product Name: Company Name
* Inactive Products
* Mantle Cell Lymphoma Key Companies
* Mantle Cell Lymphoma Key Products
* Mantle Cell Lymphoma- Unmet Needs
* Mantle Cell Lymphoma- Market Drivers and Barriers
* Mantle Cell Lymphoma- Future Perspectives and Conclusion
* Mantle Cell Lymphoma Analyst Views
* Mantle Cell Lymphoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mantle-cell-lymphoma-pipeline-appears-robust-with-20-key-pharma-companies-actively-working-in-the-domain-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.